Cargando…

Assessment of real-world application of advanced prostate cancer management in Japan

Detalles Bibliográficos
Autor principal:	Aragon-Ching, Jeanny B.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2022
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9827408/ https://www.ncbi.nlm.nih.gov/pubmed/36632149 http://dx.doi.org/10.21037/tau-22-765

Ejemplares similares

The path forward in prostate cancer therapeutics
por: Aragon-Ching, Jeanny B, et al.
Publicado: (2018)

The emerging role of prostate-specific membrane antigen (PSMA) PET-CT in patients with high-risk prostate cancer: moving the bar in high-risk prostate cancer
por: Aragon-Ching, Jeanny B
Publicado: (2020)

The Evolution of Prostate Cancer Therapy: Targeting the Androgen Receptor
por: Aragon-Ching, Jeanny B.
Publicado: (2014)

Use of early chemotherapy for hormone-sensitive prostate cancer: time for CHAARTED
por: Aragon-Ching, Jeanny B
Publicado: (2016)

The promising role of poly(ADP-ribose) polymerase inhibitors in prostate cancer
por: Aragon-Ching, Jeanny B
Publicado: (2016)

Vitamin D in prostate cancer
por: Trump, Donald L, et al.
Publicado: (2018)

Darolutamide: a novel androgen-signaling agent in nonmetastatic castration-resistant prostate cancer
por: Aragon-Ching, Jeanny B
Publicado: (2019)

ARASENS: making sense out of first-line metastatic hormone-sensitive prostate cancer treatment
por: Aragon-Ching, Jeanny B
Publicado: (2022)

Further analysis of PREVAIL: enzalutamide use in chemotherapy-naïve men with metastatic castration-resistant prostate cancer
por: Aragon-Ching, Jeanny B
Publicado: (2014)

Management of patients with advanced prostate cancer in Japan: ‘real-world’ consideration of the results from the Advanced Prostate Cancer Consensus Conference
por: Fujita, Kazutoshi, et al.
Publicado: (2022)

Radium-223 for the treatment of castration-resistant prostate cancer
por: El-Amm, Joelle, et al.
Publicado: (2015)

Multidisciplinary treatment (MDT) perspectives in renal cell carcinoma
por: Aragon-Ching, Jeanny B., et al.
Publicado: (2023)

Role of chemotherapy in prostate cancer
por: Nader, Rita, et al.
Publicado: (2018)

Advanced prostate cancer – patient survival and potential impact of enzalutamide and other emerging therapies
por: Patel, Nihar K, et al.
Publicado: (2014)

Key Difficulties Associated with Cancer Biology
por: Fang, Xiaolan, et al.
Publicado: (2016)

Targeting Bone Metastases in Metastatic Castration-Resistant Prostate Cancer
por: El-Amm, Joelle, et al.
Publicado: (2016)

The Current Landscape of Treatment in Non-Metastatic Castration-Resistant Prostate Cancer
por: El-Amm, Joelle, et al.
Publicado: (2019)

Financial toxicity differences between chemical versus surgical androgen deprivation therapy
por: Aragon-Ching, Jeanny B., et al.
Publicado: (2022)

Advances and Controversies With Checkpoint Inhibitors in Bladder Cancer
por: Rhea, Logan P, et al.
Publicado: (2021)

Role of Chemotherapy and Mechanisms of Resistance to Chemotherapy in Metastatic Castration-Resistant Prostate Cancer
por: Lohiya, Vipin, et al.
Publicado: (2016)

Enzalutamide: a new indication for nonmetastatic castration-resistant prostate cancer
por: Rhea, Logan P, et al.
Publicado: (2019)

Angiogenesis Inhibition in Prostate Cancer: Current Uses and Future Promises
por: Aragon-Ching, Jeanny B., et al.
Publicado: (2010)

Mechanistic Insights on Localized to Metastatic Prostate Cancer Transition and Therapeutic Opportunities
por: Yu, Eun-mi, et al.
Publicado: (2023)

Impact of abiraterone on patient-related outcomes in metastatic castration-resistant prostate cancer: current perspectives
por: El-Amm, Joelle, et al.
Publicado: (2017)

Metastatic Castration-Resistant Prostate Cancer: Critical Review of Enzalutamide
por: El-Amm, Joelle, et al.
Publicado: (2013)

Erratum for “Metastatic Castration-Resistant Prostate Cancer: Critical Review of Enzalutamide”
por: El-Amm, Joelle, et al.
Publicado: (2013)

Bone-Targeted Therapies in Metastatic Castration-Resistant Prostate Cancer: Evolving Paradigms
por: El-Amm, Joelle, et al.
Publicado: (2013)

Managing advanced prostate cancer in the Asia Pacific region: “Real‐world” application of Advanced Prostate Cancer Consensus Conference 2019 statements
por: Chiong, Edmund, et al.
Publicado: (2022)

Advances in Localized Prostate Cancer Management
por: Samadi, David B., et al.
Publicado: (2018)

New insights on the early prostate cancer diagnosis in a real-world setting
por: Lakshmanan, Vinoth-Kumar, et al.
Publicado: (2022)

Emerging Wearable Biosensor Technologies for Stress Monitoring and Their Real-World Applications
por: Wu, Ju-Yu, et al.
Publicado: (2022)

Balancing efficacy and quality of life measurements among metastatic renal cell carcinoma (RCC) studies
por: Aragon-Ching, Jeanny B.
Publicado: (2021)

Management of advanced prostate cancer in a middle‐income country: real‐world consideration of the Advanced Prostate Cancer Consensus Conference 2017
por: Saad, Marniza, et al.
Publicado: (2019)

Real-world use of enzalutamide in men with nonmetastatic castration-resistant prostate cancer in Japan
por: Yokomizo, Akira, et al.
Publicado: (2021)

Editorial: Radical cystectomy in bladder cancer patients
por: Koshkin, Vadim S., et al.
Publicado: (2022)

A Contemporary Review of Immune Checkpoint Inhibitors in Advanced Clear Cell Renal Cell Carcinoma
por: Yu, Eun-mi, et al.
Publicado: (2021)

Practical Applications of NMR to Solve Real-World Problems
por: Brinson, Robert G.
Publicado: (2021)

Recent Advances in Statistical Data and Signal Analysis: Application to Real World Diagnostics from Medical and Biological Signals
por: Mahapatra, Dwarikanath, et al.
Publicado: (2016)

Emerging Ethical Issues in Managing Real World Data
por: Yang, Kwang-Mo
Publicado: (2019)

Correction to: Real-world use of enzalutamide in men with nonmetastatic castration-resistant prostate cancer in Japan
por: Yokomizo, Akira, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_nla630tk5hnleru28440g0ce1f